4-((3'-fluoro)benzyloxy)benzonitrile | 831216-51-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-((3'-fluoro)benzyloxy)benzonitrile
• 英文别名: 4-((3-fluorobenzyl)oxy)benzonitrile；4-(3-fluorobenzyloxy)-benzonitrile；4-(3-fluorobenzyloxy)benzonitrile；4-[(3-Fluorophenyl)methoxy]benzonitrile
• CAS: 831216-51-4
• 化学式: C₁₄H₁₀FNO
• mdl: MFCD06626647
• 分子量: 227.238
• InChiKey: ZAAMMXIRNCLZKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-((3'-fluoro)benzyloxy)benzonitrile 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 (4-((3-fluorobenzyl)oxy)phenyl)methanamine
  参考文献：
  名称：

  Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity

  摘要：

  Several antiepileptic drugs exert their activities by inhibiting Na+ currents. Recent studies demonstrated that compounds containing a biaryl-linked motif (Ar-X-Ar') modulate Na+ currents. We, and others, have reported that compounds with an embedded benzyloxyphenyl unit (ArOCH2Ar', OCH2 = X) exhibit potent anticonvulsant activities. Here, we show that benzyloxybenzylammonium chlorides (+H3NCH2C6H4OCH2 Ar' Cl-) displayed notable activities in animal seizure models. Electrophysiological studies of 4-(2'-trifluoromethoxybenzyloxy)benzylammonium chloride (9) using embryonic cortical neurons demonstrated that 9 promoted both fast and slow inactivation of Na+ channels. These findings suggest that the potent anticonvulsant activities of the earlier compounds were due, in part, to the benzyloxyphenyl motif and provide support for the use of the biaryl-linked pharmacophore in future drug design efforts. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.031
• 作为产物：
  描述：

  4-羟基苯甲腈 、 3-氟溴苄 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 4.0h， 以95%的产率得到4-((3'-fluoro)benzyloxy)benzonitrile
  参考文献：
  名称：

  联芳基衍生物的合成和评估，用于针对帕金森氏病的选择性单胺氧化酶B抑制剂的结构表征

  摘要：

  苄氧基苯基部分是单胺氧化酶B（MAO-B），沙芬酰胺和司加吉林的高效，选择性和可逆抑制剂的常见结构。我们合成了在末端芳基单元上包含卤素取代基的4-（苄氧基）苯基和联苯-4-基衍生物。另外，我们修饰了胺基和联芳基连接单元之间的碳连接基。在合成的化合物中，12c作为竞争性抑制剂表现出最有效和选择性的MAO-B抑制作用（hMAO-B IC 50：8.9 nM；选择性比MAO-A高10,000倍）。另外，12c与著名的MAO-B抑制剂（例如司来吉兰，沙芬酰胺和sembragiline）相比，具有更高的MAO-B抑制活性和选择性。在MPTP诱发的帕金森氏病（PD）小鼠模型中，12c可显着保护酪氨酸羟化酶（TH）免疫阳性DAergic神经元，并减轻与PD相关的行为缺陷。这项研究表明，作为MAO-B抑制剂的特征结构可能为PD治疗药物的开发提供很好的见识。

  DOI：

  10.1016/j.bmc.2017.11.036

文献信息

• Novel antifungal agent containing heterocyclic compound
  申请人：Nakamoto Kazutaka

  公开号：US20070105943A1

  公开（公告）日：2007-05-10

  The present invention provides an antifungal agent represented by the formula: [wherein A 1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X 1 represents a group represented by the formula —NH—C(═O)—, a group represented by the formula —C(═O)—NH—, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A 1 may have 1 to 3 substituents, and E has one or two substituents].

  本发明提供了一种抗真菌剂，其表示为以下式子： [其中A1表示一个3-吡啶基团，可能具有取代基，喹啉基团，可能具有取代基或类似物；X1表示由公式—NH—C（═O）—，由公式—C（═O）—NH—或类似物表示的基团；E表示呋喃基团，噻吩基团，吡咯基团，苯基团，吡啶基团，四唑基团，噻唑基团或吡唑基团；但A1可能具有1到3个取代基，E具有一个或两个取代基。]
• Novel Antimalarial Agent Containing Heterocyclic Compound
  申请人：Nakamoto Kazutaka

  公开号：US20090227799A1

  公开（公告）日：2009-09-10

  Disclosed is an antimalarial agent containing a compound represented by the formula: [wherein A 1 represents a 3-pyridyl group that may have a substituent, a 6-quinolyl group that may have a substituent, or the like; X 1 represents a group represented by the formula —C(═O)—NH— or the like; E represents a furyl group, a thienyl group or a phenyl group; with the proviso that A 1 may have one to three substituents, and E has one of two substituents] or a salt thereof or hydrates thereof.

  揭示了一种抗疟疾剂，其包含由下式表示的化合物： [其中A1表示一个3-吡啶基团，可以有取代基，一个6-喹啉基团，可以有取代基或类似物；X1表示一个由公式-C（═O）-NH-或类似物表示的基团；E表示一个呋喃基团，噻吩基团或苯基团；但前提是A1可以有1到3个取代基，E有两个取代基之一]或其盐或水合物。
• NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND
  申请人：NAKAMOTO Kazutaka

  公开号：US20110195999A1

  公开（公告）日：2011-08-11

  The present invention provides an antifungal agent represented by the formula: wherein A 1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X 1 represents a group represented by the formula —NH—C(═O)—, a group represented by the formula —C(═O)—NH—, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A 1 may have 1 to 3 substituents, and E has one or two substituents.

  本发明提供一种抗真菌剂，其化学式如下： 其中，A1代表3-吡啶基，可以有取代基，喹啉基，也可以有取代基等；X1代表由公式—NH—C（═O）—，由公式—C（═O）—NH—等表示的基团；E代表呋喃基，噻吩基，吡咯基，苯基，吡啶基，四唑基，噻唑基或吡唑基；但要求A1可能有1到3个取代基，E有1或2个取代基。
• Antifungal agent containing heterocyclic compound
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US07932272B2

  公开（公告）日：2011-04-26

  The present invention provides an antifungal agent represented by the formula: [wherein A1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X1 represents a group represented by the formula —NH—C(═O)—, a group represented by the formula —C(═O)—NH—, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A1 may have 1 to 3 substituents, and E has one or two substituents].

  本发明提供了一种抗真菌剂，其化学式如下：[其中A1代表3-吡啶基，可以具有取代基，喹啉基，也可以具有取代基等；X1代表由公式—NH—C（═O）—，由公式—C（═O）—NH—等表示的基团；E代表呋喃基，噻吩基，吡咯基，苯基，吡啶基，四唑基，噻唑基或吡唑基；限制条件是A1可以有1到3个取代基，E有一个或两个取代基]。
• Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents
  申请人：Kohn Harold L.

  公开号：US20120232015A1

  公开（公告）日：2012-09-13

  A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula Ia, or more particularly Formula Ib, or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.

  本发明的第一个方面是公式Ia的化合物（有时也在此处称为“活性剂”或“活性化合物”）或更具体地为公式Ib的化合物，或其药物可接受的盐或前药。还描述了其组成物和使用方法（例如，用于治疗神经系统疾病）。